Opinion
“Let the activists keep beating the drum around female health inequalities”
By Nicola Finn, associate director at OggaDoon

For decades medical research has been based on data from the male body, but we now know that women’s bodies respond in different ways to drugs and disease.
The research and application gap in healthcare is starting to be recognised and thankfully, the landscape is changing. After all women account for 50 per cent of the global population.
We are going to witness a massive explosion in female health solutions over the next five years. Femtech is predicted to grow at around 15 per cent CAGR, with solutions around mental health, ovarian health, menstrual health and menopause health – to name a few.
More female founders who connect and understand the different health challenges women face are starting businesses to help fill the female health gap in different ways. However, this is not for the faint of heart as the female founders must overcome other barriers such as the bias in capital funding, access to business loans and support for childcare to help free up women’s time.
In the UK, there is a widening funding gap between male-founded and female-founded companies. In 2020, just 2.3 per cent of VC funding went to women-led start-ups. This fell to 1.7 per cent in 2021.
There is additional research conducted by Extended Ventures which also spotlighted the huge investment gap facing diverse founders over the past decade, according to race, gender and educational background, with all-ethnic teams and female entrepreneurs receiving just a fraction of available funding versus all-white teams and male founders. The finding of baked-in bias holds true across all funding stages, per the findings.
Lack of diversity across the capital landscape – angel, venture capital (VC) or private equity (PE) – is no secret. At present, it is a male-dominated space globally.
In 2019 women comprise 30 per cent of venture capital personnel – a small increase from 27 per cent in 2017. Whilst this is encouraging and implies more representation, it still lags behind the average of UK working professionals.
All groups of humans have similar biases, naturally gravitating to people and scenarios that they can personally relate to. This extends to bias around investment decisions, intentional or not. But we need more female investors to be in these positions, as they can personally understand the impact of innovations, specifically targeting female health.
After years of male investors ignoring the female health space, it is finally being recognised as a hotbed for investment due to its predicted growth.
Thankfully, more women are coming into the female health investment industry and more funds are also headed by female investors.
This is needed to drive and ensure inclusivity and unbiased access to the industry and will need historic investment for innovation and collaboration.
In order to build towards the brave new world that prioritises individual female needs in healthcare, there needs to be a movement. Not just front-line activists championing and fighting for equality in female health, but also activist angels, VCs and PEs, providing funding support to visionary founders.
Right now, it is a critical time to keep taking those meaningful steps to bridge the gender health gap. With that, here are some of the UK femtech founders bridging the gender health gap:
Sarah Bolt, founder of Forth has always been part of the movement to highlight and bridge the female gender data and health inequality gap. Forth’s mission is to empower women to become experts on their own body through scientific knowledge and understanding. Historically, women’s bodies were deemed too complicated for clinical trials due to the complexities of their hormone network. This has resulted in women reacting differently to drugs and often misdiagnosed as they do not present with the same symptoms as men.
It was only six years ago that the National Institutes of Health required medical investigators to consider sex as a biological variable. But there is still a long way to go in closing the gender data gap in health.
Forth’s contribution to closing this gap in data is their ground-breaking solution MyFORM™, an advanced female hormone blood test that addresses the lack of clinical insight from current single day hormone blood tests. The single-day tests assume every woman has an average length cycle of 28 days and offer little in the way of personalisation.
MyFORM™ uses a combination of blood analysis, advanced mathematical modelling and endocrinology expertise to scientifically map how a woman’s hormones are fluctuating across their entire menstrual cycle rather than a single day.
With two blood tests taken on day 14 and day 21, the test is able to predict the woman’s own cycle length, creating charts of her four key female hormones across her menstrual cycle, as well as providing personalised ranges for each hormone.
Forth has also developed a unique way to assess a woman’s ovarian health. The Forth Ovarian Response Metric (FORM) takes the results from the blood tests to provide a score on how well a woman’s ovaries are responding to her control hormones. A score above 75 indicates a healthy hormone network. This is particularly useful for women entering perimenopause when their ovaries begin to become less responsive.
The product is designed for women who are experiencing natural menstrual cycles and not using any hormonal treatments such as the pill, Mirena coil or hormone replacement therapy (HRT). It is particularly useful for:
- Women who want to check for hormone imbalance
- Women in their 40s who want to understand if the symptoms they are experiencing are due to perimenopause
- To identify or manage an existing hormone related condition
- Women who consider starting a family
- Exercisers, athletes and dancers who want to perform to their personal best throughout their cycle and ensure their hormones have not been compromised by their training load and fuelling strategies
- Women whose menstrual cycles have recently resumed following recovery from RED-S – relative energy deficiency in sport – discontinuation of hormonal contraception or in the postnatal period.
The highly accurate, personalised results are based on eight hormone measurements, which are translated through AI and delivered on the Forth app. This offers scientific data and actionable insights as hormones are intrinsically linked to a woman’s wellbeing and have an important role to play not only in fertility but in heart health, bone health and the nervous system.
Dr Chen Mao Davies started LatchAid after facing her own struggles with breastfeeding, pain and subsequent depression. She realised that mothers needed maternal support fit for the 21st century in an interactive way.
With the pandemic currently paralysing the predominantly face-to-face support model in place, her app is more necessary now than ever.
LatchAid supports breastfeeding mums and their families through interactive 3D technology, artificial intelligence, virtual peer support groups and live healthcare specialists to combat problems experienced with the latching technique. The app prides itself on being inherently accessible and democratic, empowering women everywhere, regardless of their economic or environmental circumstances.
As well as positive health outcomes for mothers and babies, breastfeeding offers social, economic, and environmental benefits. The UK, however, has the lowest breastfeeding rate in the world. 90 per cent of women give up breastfeeding before they want to because of pain, health issues or lack of support. Unsuccessful breastfeeding also costs society around US$1B per day globally.
LatchAid is an app that utilises 3D interactive technology to help mothers learn breastfeeding skills intuitively from 3D avatars. It offers virtual peer support groups to connect mothers to a close-knit peer-to-peer support network and an AI-powered virtual supporter chatbot to provide users with personalised expertise and companionship 24/7.
Elvie is a women’s healthcare company providing products which take women’s tech out of the dark ages. Tania Boler started the business after working on women’s health policy for global NGOs and the United Nations.
She believes that the release of health products targeting a female audience must go alongside the breaking down of societal stigmatisation of women’s health.
One such product is the sleek, innovative breast pump – the smallest and lightest wearable electric one on the market. It is a silent, wire-free, fully electric device that fits subtly into a nursing bra, ensuring new mothers can pump whilst moving around comfortably.
The pump connects to a mobile app which releases a notification when the bottles are filled. The app can also be used to adjust the suction, monitor pumping history, monitor real-time milk levels and pause and start pumping. The product also includes bra adjusters to ensure less pressure on the breast.
Another product by Elvie is the pelvic floor trainer. Now available on the NHS, this product connects to the Elvie app and encourages training with fun games for five minutes, three times a week.
The trainer is fully waterproof, rechargeable and covered with medical-grade silicone and it is safe to use with an IUD and coil. The app encourages use with four different skill levels and six different exercise types including strength and lift.
Kim Palmer founded the women’s mental health app Clementine in 2017 which uses hypnotherapy to lower stress levels and build confidence. She created Clementine after suffering herself from panic attacks during pregnancy. The app has both a free and a subscription-based version with sleep sessions, confidence and anti-anxiety courses as well as mantras.
Deborah Brock founded Nua Fertility following the challenges she had through her own fertility journey. Following her own successful pregnancy through optimising diet, she started researching the connection between the gut microbiome and reproductive health. After three years of research, Deborah developed two fertility supplements – one for men and one for women – that focus on the microbiome to optimise fertility health.
Nua fertility supplements, have a microbiome focus and are designed to support the nutritional needs of men and women when trying to conceive. The company’s NuaBiome Women supplements combine fertility-supporting vitamins and minerals with a blend of strains of good bacteria to promote healthy conception, egg health, and foetal development.
The friendly bacteria offer three significant benefits: absorption of essential fertility vitamins and nutrients, strengthening the immune system and reducing inflammation in the body.
All these female founders have fought to gain funding for their propositions and succeeded despite the obstacles due to the baked-in bias and lack of diversity across the business capital arena.
However, more female investors need to be appointed as they can personally understand the impact of female health tech innovations.
Let the activists keep beating the drum around female health inequalities. As we continue to make these meaningful steps to bridge the gender health gap we can remember that necessity is the mother of all invention.
News
Why advocacy-orientated CPD matters for the future of cardiology

By Women As One
At the 2026 Alliance Annual Conference, Women As One presented a poster that asked a powerful question: What if continuing professional development (CPD) did more than teach clinical knowledge— and instead helped shape the future of the workforce itself?
For decades, professional education in medicine has focused primarily on what clinicians know and how they practice. That work remains essential.
But persistent gender gaps across cardiology—from leadership positions to research participation and speaking opportunities—demonstrate that knowledge alone is not enough to ensure equitable advancement.
To truly strengthen the field of cardiology, professional development must also support who clinicians become, the opportunities they access, and the voices that shape the future of cardiovascular medicine.
Our poster, More Than Education: Elevating Equity and Identity Through CPD, explores how a new model of advocacy-orientated CPD can help close these gaps.
Advocacy-orientated CPD expands the traditional model of professional education. In addition to building clinical expertise, it intentionally supports the structural elements that shape career advancement—mentorship, sponsorship, leadership development, visibility, and professional networks.
By integrating these elements into professional education, CPD can become a powerful engine for advancing equity—and ultimately improving patient care.
Why this matters
Gender inequities in medicine are not simply workforce issues. They influence research priorities, clinical trial representation, leadership decision-making, and ultimately the care patients receive.
When women clinicians have equitable opportunities to lead, research, and shape clinical practice, the entire healthcare system benefits.
Yet structural barriers remain. Women physicians often have less access to mentorship, sponsorship networks, and leadership pathways—factors that are critical for career advancement.
This is where advocacy-orientated CPD comes in.
By intentionally designing programs that foster mentorship, build leadership skills, create visibility, and support long-term professional growth, organizations can help ensure that the next generation of cardiovascular leaders reflects the diversity of the patients they serve.
Turning opportunity into impact
Since its founding, Women As One has supported thousands of women cardiologists across more than 100 countries, expanding access to mentorship, research opportunities, and leadership development.
Through programs like CLIMB, RISE, Mentorship Awards, and our global digital community, The Pulse, thousands of women cardiologists have gained mentorship, leadership training, and opportunities that accelerate their careers and expand their influence.
Today, the outcomes of these programs are shaping the field in tangible ways:
- Women As One alumnae are leading clinical trials and advancing cardiovascular research
- Clinicians supported through our programs are building registries, launching new care models, and expanding access to specialized care
- Women cardiologists are gaining greater representation on speaker panels, advisory boards, and leadership pathways
- A global community of more than 3,000 women cardiologists is strengthening collaboration, mentorship, and visibility across the profession
These outcomes demonstrate what becomes possible when professional development goes beyond traditional education to intentionally support leadership, identity, and community.
A call to the cardiovascular community
Advancing equity in cardiology is not the responsibility of one organization—it requires a collective effort across the entire ecosystem of clinicians, educators, institutions, and industry partners.
For women cardiologists, this means engaging in the programs, mentorship networks, and leadership opportunities that help shape the future of the field. Whether through CLIMB, RISE, research initiatives, or participation in The Pulse community, your involvement strengthens a growing movement dedicated to advancing women in cardiology.
For our partners and supporters, this work demonstrates the powerful impact that strategic investment in equity-focused professional development can have on the workforce and the patients we ultimately serve.
Together, we can redefine what professional development looks like in medicine—not just as a pathway for learning, but as a catalyst for leadership, opportunity, and lasting change.
Explore the poster
We invite you to explore the poster below (click here to download it) to learn more about the evidence, framework, and real-world impact behind this work—and to join us in continuing to expand what professional development can achieve for the future of cardiovascular medicine.
Learn more about Women As One at womenasone.org

Opinion
What Maternal Mental Health Month reveals about where postpartum support actually breaks down

By Morgan Rose, chief science officer at Ema, and Lauren Scocozza, vice president of product at Willow
May is Maternal Mental Health Month, and every year it surfaces a familiar set of statistics: 1 in 5 new mothers experiences postpartum depression or anxiety, most go unscreened, and the majority who are screened don’t receive adequate follow-up care.
The conversation is important. But the numbers obscure something that anyone who has worked in this space knows to be true: postpartum mental health distress rarely arrives with a label.
It arrives as exhaustion. As “I’m not sure I’m doing this right.”
As a question about supply, pumping, whether it’s okay to feel this disconnected from something you were supposed to love immediately.
Willow integrated Ema, AI built for women’s health, with the goal of closing the maternal care and data gap.
The pattern mentioned above appears consistently in Ema’s conversational data through the Willow app.
A mother reports mastitis symptoms.
Ema walks her through the clinical presentation, confirms she should keep pumping, and then she questions if she is using her pump correctly. In the same thread, within a few exchanges, she says she’s “feeling too sad.” Then: “I don’t know. I think I’m depressed. I am not enjoying my postpartum.”
She did not come to the app to talk about her mental health.
She came about a breast infection. The mental health disclosure came through the already-opened door.
The Weight Underneath the Technical Question
New motherhood involves an enormous amount of problem-solving at a time when cognitive and emotional reserves are depleted. The pump has to work. The baby has to eat. The body has to recover.
Work comes back. Sleep doesn’t. Feeding their babies requires skill, and the learning curve sits atop it all.
What Ema’s conversation data shows is that the emotional load of navigating these challenges is not separate from mental health. It is mental health.
When a mother writes, “I’m postpartum and overwhelmed and tired,” and then, in the same breath, asks about flange sizing, she is telling us what the postpartum experience actually feels like from the inside.
The technical question and the emotional state are one and the same.
Breastfeeding carries particular weight here.
The desire to breastfeed, the guilt when it doesn’t go as planned, and the identity questions that come with feeding choices are not peripheral to the postpartum mental health conversation.
In our conversations, women navigating supply concerns often reveal deeper anxieties: about whether they are good mothers, whether their bodies are “working,” and whether the difficulty they are experiencing means something about them.
These are the signals worth asking about.
What Screening Looks Like in Practice
Ema is trained on the Edinburgh Postnatal Depression Scale and is equipped to offer the EPDS when a conversation warrants it.
The value is being present for the moment when a woman is ready to name what she’s feeling.
That moment rarely comes as a direct request for mental health support. It comes when someone is already in a conversation about something else, and something shifts.
A woman dealing with mastitis says she feels sad. A woman worried about supply says she doesn’t feel like herself. A woman managing the logistics of going back to work with a wearable pump says she’s not sure she can keep up with it all — and the “it all” isn’t about the pump.
Ema is designed to hear that. She doesn’t stay on the clinical or technical track when the conversation moves. She follows the person.
And when the moment is right, she offers the screening as a natural next step.
In one exchange, a woman was offered the EPDS after disclosing depressive feelings. She declined.
Ema acknowledged that and asked if she wanted to talk about something else. That’s the right response. The offer was made without pressure. The door stays open.
Sometimes what matters most is that someone asked at all.
The Continuity Problem
One of the most persistent structural failures in maternal mental health care is fragmentation.
A woman sees her OB at six weeks postpartum for a brief screening. She may get a call from a nurse. She may be given a referral she never follows up on because she doesn’t have the capacity to navigate a new care relationship while managing a newborn.
The clinical touchpoints are too few, too far apart, and too often siloed from one another.
The postpartum period lasts far longer than the six-week checkup implies. Mental health symptoms can emerge weeks or months after delivery, shift in character over time, and interact with physical challenges in ways that don’t fit neatly into any single provider’s lane.
A lactation concern becomes an anxiety spiral. A supply drop triggers a grief response. A difficult return to work surfaces a postpartum depression that wasn’t fully recognized at six weeks.
Ema sits inside these moments because she’s embedded in the platform women are already using. She doesn’t require a separate appointment, a referral, or the cognitive bandwidth to seek out a new resource.
She’s in the Willow app that mom is already using multiple times a day to manage her pump.
When Ema identifies a woman who may need more support than she can provide, she routes to the right resource — whether that’s a SimpliFed lactation consultant for feeding-related concerns or a clinical professional for mental health follow-up.
The conversation leads to the handoff with someone who can do more.
What the Month of May Means for the Rest of the Year
Maternal Mental Health Month is a useful moment of attention. The awareness campaigns, the social media posts, and the statistics shared in newsletters matter.
But the gap in postpartum mental health care is not really an awareness problem.
Most people in the perinatal space and beyond know the statistics. The problem is access, timing, and continuity.
AI doesn’t close that gap on its own.
What it can do is be present in the spaces where women already are, at the times when they need something, and attentive enough to recognise that a conversation about a pump, a clogged duct, or a supply concern is also a conversation about how someone is doing.
The question behind the question is often the more important one.
For Willow, the conversation data Ema generates is a map of where mothers are struggling, what they reach for when they need help, and when they are ready to say more than they came to say.
That information, used well, shapes better resources, better onboarding, and a more connected experience across the full arc of the postpartum year and beyond.
Building the infrastructure to support maternal mental health is a year-round project.
Willow is doing one part of that, and the conversations happening on the Willow platform every day are evidence that women want support that meets them where they are… in their app, in their moment, without having to ask for it twice.
About the authors
Morgan Rose is Chief Science Officer at Ema, an AI platform for women’s health. Ema partners with healthcare organisations and femtech companies to deliver clinically grounded AI support across the perinatal journey.
Lauren Scocozza is the Vice President of Product at Willow Innovations, Inc. For women by women, Willow is building a maternal care platform to address the interconnected challenges of postpartum.
Opinion
Femtech’s next chapter: Building a truly equal and comprehensive health tech category

By Wolfgang Hackl, MD, CEO OncoGenomX, Allschwil, Switzerland
FemTech is moving from a promising niche to a foundational part of modern healthcare.
Over the next decade and beyond, its real promise will not only be better products, but a more equitable system: one where women’s health is treated as an equal area for innovation, investment, clinical care, and public policy.
That shift matters because women’s health has long been under-researched, underfunded, and too often managed through systems that were not designed with female biology and life stages in mind.
The opportunity now is to change that trajectory.
If stakeholders act deliberately, FemTech can become a category that improves outcomes, expands access, and creates measurable value across the HealthTech ecosystem.
From niche to infrastructure
The most important change ahead is a mindset shift. FemTech should no longer be seen as a narrow consumer segment focused only on logging symptoms.
It should be understood as health infrastructure spanning puberty, fertility, pregnancy, postpartum recovery, menopause, pelvic health, chronic disease, mental health, and long-term preventive care.
This broader framing creates a more durable market and a stronger social case. It also encourages innovation that serves people across the full life course, rather than only at highly visible moments.
In practical terms, this means building tools that are clinically relevant, integrated into care pathways, and designed to work for different populations and health systems.
What needs to change
For FemTech to become a truly equal healthcare category and a genuine societal priority, several layers need to move together.
First, the evidence base must deepen. More sex-disaggregated data, more women-inclusive clinical studies, and more research on conditions that disproportionately affect women are essential.
Without stronger evidence, product development, diagnosis, reimbursement, and clinical adoption all remain constrained.
Second, policy and regulation must mature. Privacy protections need to be strong enough to build trust in highly sensitive health data.
Regulatory pathways should be clear enough to help innovators bring safe, effective products to market without unnecessary delay.
Reimbursement frameworks also need to evolve so that useful digital tools are not limited to those who can pay out of pocket.
Third, healthcare systems must become more open to integration. The best FemTech products should not sit outside the care journey as standalone apps.
They should connect with clinicians, diagnostics, telehealth, and care coordination so that patients experience continuity rather than fragmentation.
Finally, society needs a broader cultural shift. Women’s health should be discussed as a mainstream public health and economic issue, not as a side topic or a private concern.
That means normalizing conversations around menopause, miscarriage, postpartum health, chronic pain, infertility, and long-term preventive care.
The role of each stakeholder
A healthier FemTech future depends on the full value chain.
Founders and product teams need to design for clinical relevance, usability, and trust. The strongest solutions will be those that solve real problems, use data responsibly, and fit into everyday life and care.
Investors can help by backing long-term value creation rather than only consumer growth. FemTech deserves capital that supports rigorous validation, regulatory readiness, and scalable business models.
Healthcare providers and systems play a critical role in adoption. By integrating FemTech into clinical workflows, they can reduce delays in care, improve monitoring, and make support more continuous and personalised.
Payers and insurers can accelerate access by recognising the downstream value of early intervention, prevention, and better self-management. Coverage decisions will strongly shape which innovations become standard practice.
Policymakers and regulators should create environments where safety, innovation, and privacy coexist. Clear standards and supportive reimbursement policy can make the difference between isolated success and category-wide growth.
Employers and public institutions also have a role. Women’s health affects productivity, retention, and long-term wellbeing, which means workplace benefits and public programs can help expand access and reduce inequity.
FemTech is not only “women for women.” It is “everyone to solve a health and social issue that has been ignored for far too long.”
When stakeholders across the value chain recognise women’s health as a shared responsibility, FemTech moves from a segmented category to a mainstream force for better outcomes, fairer access, and stronger social impact.
Why the upside is larger than the market
The benefit of getting this right is not only commercial.
Better women’s health tools can improve early detection, support self-management, reduce avoidable complications, and lower the burden on social and healthcare systems.
They can also help close persistent gaps in access and outcomes that affect families, workplaces, and economies.
For HealthTech innovators, this is an opportunity to build products that are both mission-driven and scalable. For health systems, it is a chance to improve care quality and efficiency. For society, it is a way to move women’s health from an afterthought to an equal priority.
Actions that will move the field forward
The right direction will not happen automatically. It requires deliberate action across the ecosystem.
- Build products around real clinical needs, not only consumer engagement.
- Invest in women-inclusive research and validation from the start.
- Design privacy and governance into the product architecture.
- Create reimbursement models that reward prevention and continuity.
- Integrate FemTech into mainstream care pathways.
- Expand education for clinicians, employers, and the public.
- Expand the category to the invisible concerns to cover the full range of women’s health needs.
When these actions align, FemTech can mature into something larger than a market category. It can become a model for how health innovation should work: evidence-based, inclusive, trusted, and built to improve lives at scale.
A strong FemTech future is not just possible. It is a practical next step if the ecosystem chooses to treat women’s health as what it truly is: a core healthcare priority and a major driver of innovation.
Table: FemTech Focus Areas
| Field | Approximate number of active solutions/companies |
| Reproductive health & fertility | 120+ |
| Pregnancy & maternal care | 80+ |
| Menstrual health | 60+ |
| General women’s health & wellness | 50+ |
| Diagnostics & monitoring | 45+ |
| Menopause & perimenopause | 40+ |
| Pelvic & uterine health | 30+ |
| Chronic women’s health / integrated care | 30+ |
| Sexual health & wellness | 25+ |
Legend: FemTech is becoming a multi-category healthcare layer. Reports also show that software/apps remain the largest product type overall, while reproductive health continues to dominate as an application area. Best-effort estimates based on category listings, company directories, and market reports, not audited totals.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Mental health4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’













12 Comments